Further combinations of lenalidomide with anti-CD20 and anti-CD19 mAbs are being explored in patients with CLL as well as investigation into its use as a maintenance therapy or in those with high-risk but early-stage disease [42]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.